Eyebright Ebitda from 2010 to 2024

688050 Stock   90.61  1.90  2.05%   
Eyebright Medical's EBITDA is increasing over the years with slightly volatile fluctuation. Overall, EBITDA is expected to go to about 384 M this year. From 2010 to 2024 Eyebright Medical EBITDA quarterly data regression line had arithmetic mean of  106,921,464 and r-squared of  0.77. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
365.7 M
Current Value
384 M
Quarterly Volatility
144.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Eyebright Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eyebright Medical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 70.9 M, Interest Expense of 10.3 M or Selling General Administrative of 226.9 M, as well as many indicators such as . Eyebright financial statements analysis is a perfect complement when working with Eyebright Medical Valuation or Volatility modules.
  
This module can also supplement various Eyebright Medical Technical models . Check out the analysis of Eyebright Medical Correlation against competitors.

Currently Active Assets on Macroaxis

Other Information on Investing in Eyebright Stock

Eyebright Medical financial ratios help investors to determine whether Eyebright Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eyebright with respect to the benefits of owning Eyebright Medical security.